.png)
SAN DIEGO & PARIS - Scientist.com, the life science industry’s leading online marketplace for outsourced research, and the Brain and SpineInstitute incubator, iPEPS-ICM, the first innovation accelerator dedicated to brain diseases in France, are partnering to launch a call for biotech startups developing novel approaches to fighting CNS diseases as part of a pitch competition.
This startup call is aimed at helping young biotechentrepreneurs to fast track the development of their innovative projects in oneof the most thriving research and innovation ecosystems in Europe. This competition is open to biotechstartups worldwide in existence for less than two years developing a noveltherapeutic and/or diagnostic approach with a main focus on central nervoussystem diseases (neuro-oncology, psychiatry, neurological disorders orpreventive health).
“In the field of disease of the nervous system; theprobability that drug candidates reach the market is only 7%, compared with anaverage of 15%,” stated Julien Elric, iPEPS incubator manager, “This outcomemakes it very difficult for young enterprises to establish in biotechnology.This startup competition is here to help young entrepreneurs to develop theirinnovation in the best environment.”
Applications can be submitted from May 28, 2018 through July 16, 2018. An expert panel of judges will narrow the applicant field to 12 in its initial round of selections in early September. A second round of selections occurring in mid-September will determine the winner and one runner up. The winner will have the opportunity to pitch the project to an audience of investors and experts at an event scheduled for late September.
The grand prize winner receives 6 months free rent atiPEPS’ state-of-the-art facilities located in Paris’ 13th district, includingconsulting with experts in preclinical/clinical development as well as $10K in research services providedthrough the Scientist.com marketplace. One runner-up willreceive 3 months free rent at iPEPS and $6K in research services through the Scientist.commarketplace.
“Neurologicaldisorders affect almost a billion people globally,” commented Dan Kagan, PhD,COO of Scientist.com. “This science-based competition highlights novel approaches tothese types of diseases and provides two early-stage companies the opportunityto take the next step in the development of their innovative ideas.”
About The Brain and Spine Institute
Located in the heart of the Pitié-SalpêtrièreUniversity Hospital Center, the first neurology hospital in France, The brainand spine institute (ICM) is a strong link between basic research and theclinical world. The Institute consists of over 700 researchers and clinicians,17 cutting-edge technological platforms and 1000m² office space intended forincubation of startups. The objective is to produce ambitious research bycombining scientific creativity and therapeutic purpose.
For furtherinformation, please contact:
Axelle de Chaillé
axelle.dechaille@icm-institute.org
+33 (0)1.57.27.47.02 / +33 (0)7.63.31.55.96
Mathilde Gratiot
mathilde.gratiot@icm-institute.org
+ 33(0)1.57.27.41.87
.webp)
Scientist.com
Scientist.com is the world’s largest and first platform built for the intricacies of scientific outsourcing.
We help pharmaceutical and biotechnology organizations discover, engage, manage, and scale relationships with the providers that support every stage of the pipeline—from discovery and preclinical research to clinical development, manufacturing, medical affairs, and commercialization. Through a centralized platform, organizations can access a global network of 6,000+ providers, streamline sourcing and procurement workflows, maintain compliance, manage supplier relationships, and leverage data-driven insights to make faster, more informed decisions.
Today, Scientist.com supports more than 130 life science organizations, including 24 of the world's top 30 pharmaceutical companies, helping teams reduce operational complexity, accelerate timelines, and bring innovations to patients faster. Our mission is to make it possible to cure all human disease by 2050.